captainmorgan
Well-Known Member
Times Square for New Years Eve will be a super spreader event like we've never seen before here, remember that there was a very large festival just before Delta cases exploded in India.
Omicron
- Thread starter schuylaar
- Start date
CunningCanuk
Well-Known Member
I’m surprised it isn’t cancelled. There’s still time. I think the cases will be so high in a couple of weeks it’ll be cancelled.
captainmorgan
Well-Known Member
But what about freedumb?
CunningCanuk
Well-Known Member
New York is going into lockdown soon. SNL last night had 2 cast members and no audience. Things are getting ugly. Most of the writers and players tested positive. Unfortunately Michael Che tested negative and even Tina Fey couldn’t save Weekend Update.
captainmorgan
Well-Known Member
Not good if accurate.
captainmorgan
Well-Known Member
These omicron numbers are all over the place, Denmark is showing lower severity and death, so which is it.
twentyeight.threefive
Well-Known Member
How do these numbers plot vs fully vaccination people? Context is key. South Africa probably has lower fully vaccinated population vs. Denmark.
Fogdog
Well-Known Member
Mardis Gras in New Orleans 2020 ----->Hospital filled with dying Covid patients
Why New Orleans Pushed Ahead With Mardi Gras, Even as It Planned for Coronavirus (Published 2020)
A cache of internal emails reveals city officials believed chances were “low” that the festivities would help spread the virus, a prediction that proved tragically off base.
captainmorgan
Well-Known Member
Yeah there's a lot of countries that don't come close to representing the same population profile of the US. South Africa has a much younger population, they also have a large number of immune compromised HIV patients and a lot of migrant workers.
Budzbuddha
Well-Known Member
Meet your enemies ….
Omicron
Delta
Current spread
Most likely the true after effects of the 2 back to back holidays ( Christmas and New Years ) will not be realized until mid January 2022.
As infection data / hospitalizations / case loads are tallied afterwards and compared to computer models . Israel is even currently running a “ war game “ approach to simulate scenarios with a deadly “ OMEGA “ variant.
Omicron
Delta
Current spread
Most likely the true after effects of the 2 back to back holidays ( Christmas and New Years ) will not be realized until mid January 2022.
As infection data / hospitalizations / case loads are tallied afterwards and compared to computer models . Israel is even currently running a “ war game “ approach to simulate scenarios with a deadly “ OMEGA “ variant.
captainmorgan
Well-Known Member
U.S. Senator Elizabeth Warren tests positive for COVID-19.
captainmorgan
Well-Known Member
U.S. Senator Cory Booker tests positive too.
captainmorgan
Well-Known Member
Both have mild symptoms.
printer
Well-Known Member
Standard drugs used to fight COVID-19 may not work against Omicron: U.S. doctors
As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs they’ve used to fight infections are unlikely to work against the new strain.
For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.
But both drugmakers recently warned that laboratory testing suggests their therapies will be much less potent against omicron, which contains dozens of mutations that make it harder for antibodies to attack the virus. And while the companies say they can quickly develop new omicron-targeting antibodies, those aren’t expected to launch for at least several months.
A third antibody from British drugmaker GlaxoSmithKline appears to be the best positioned to fight omicron. But Glaxo’s drug is not widely available in the U.S., accounting for a small portion of the millions of doses purchased and distributed by the federal government. U.S. health officials are now rationing scarce drug supplies to states.
“I think there’s going to be a shortage,” said Dr. Jonathan Li, director of the Harvard/Brigham Virology Specialty Laboratory. “We’re down to one FDA-authorized monoclonal antibody” with omicron because of the reduced effectiveness of Regeneron and Lilly’s drugs.
Glaxo’s drug, developed with Vir Biotechnology, was specifically formulated to bind to a part of the virus that is less likely to mutate, according to the companies. Early studies of laboratory-simulated omicron by the drugmakers and outside researchers show promising results.
Supply of the drug is “extremely limited, and additional doses of the product will not be available until the week of January 3rd,” the U.S. Department of Health and Human Services said in an statement posted online.
After pausing distribution last month to conserve supply, HHS is now shipping 55,000 doses of the drug, called sotrovimab, to state health departments, with the doses arriving as early as Tuesday. An additional 300,000 are expected in January.
HHS recommends states conserve the drug for the highest risk patients who are most likely to have omicron infections, either based on laboratory testing that can identify the variant or elevated levels of omicron spread in local communities, identified as 20% and higher.
High-risk patients include seniors and those with serious health problems, such as obesity, heart disease, diabetes and immune-system disorders.
Prior to the pause in shipments, Glaxo’s drug accounted for about 10% of the 1.8 million antibody doses distributed to state health officials between mid-September and late November, according to federal figures.
The loss of two leading antibody therapies puts even more focus on a pair of highly anticipated antiviral pills that U.S. regulators are expected to soon authorize.
The drugs from Pfizer and Merck would be the first treatments Americans can take at home to head off severe disease. Pfizer’s drug in particular has shown a powerful effect, curbing hospitalizations and deaths by nearly 90% in high-risk patients.
“If it’s rolled out effectively this has a real big potential,” to make up for antibody treatments, said Andrew Pekosz, a virologist at Johns Hopkins University. “That’s an immediate place where these antivirals could minimize the impact of omicron.”
globalnews.ca
As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs they’ve used to fight infections are unlikely to work against the new strain.
For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.
But both drugmakers recently warned that laboratory testing suggests their therapies will be much less potent against omicron, which contains dozens of mutations that make it harder for antibodies to attack the virus. And while the companies say they can quickly develop new omicron-targeting antibodies, those aren’t expected to launch for at least several months.
A third antibody from British drugmaker GlaxoSmithKline appears to be the best positioned to fight omicron. But Glaxo’s drug is not widely available in the U.S., accounting for a small portion of the millions of doses purchased and distributed by the federal government. U.S. health officials are now rationing scarce drug supplies to states.
“I think there’s going to be a shortage,” said Dr. Jonathan Li, director of the Harvard/Brigham Virology Specialty Laboratory. “We’re down to one FDA-authorized monoclonal antibody” with omicron because of the reduced effectiveness of Regeneron and Lilly’s drugs.
Glaxo’s drug, developed with Vir Biotechnology, was specifically formulated to bind to a part of the virus that is less likely to mutate, according to the companies. Early studies of laboratory-simulated omicron by the drugmakers and outside researchers show promising results.
Supply of the drug is “extremely limited, and additional doses of the product will not be available until the week of January 3rd,” the U.S. Department of Health and Human Services said in an statement posted online.
After pausing distribution last month to conserve supply, HHS is now shipping 55,000 doses of the drug, called sotrovimab, to state health departments, with the doses arriving as early as Tuesday. An additional 300,000 are expected in January.
HHS recommends states conserve the drug for the highest risk patients who are most likely to have omicron infections, either based on laboratory testing that can identify the variant or elevated levels of omicron spread in local communities, identified as 20% and higher.
High-risk patients include seniors and those with serious health problems, such as obesity, heart disease, diabetes and immune-system disorders.
Prior to the pause in shipments, Glaxo’s drug accounted for about 10% of the 1.8 million antibody doses distributed to state health officials between mid-September and late November, according to federal figures.
The loss of two leading antibody therapies puts even more focus on a pair of highly anticipated antiviral pills that U.S. regulators are expected to soon authorize.
The drugs from Pfizer and Merck would be the first treatments Americans can take at home to head off severe disease. Pfizer’s drug in particular has shown a powerful effect, curbing hospitalizations and deaths by nearly 90% in high-risk patients.
“If it’s rolled out effectively this has a real big potential,” to make up for antibody treatments, said Andrew Pekosz, a virologist at Johns Hopkins University. “That’s an immediate place where these antivirals could minimize the impact of omicron.”
Standard drugs used to fight COVID-19 may not work against Omicron: U.S. doctors - National | Globalnews.ca
The shrinking toolbox of treatments is a painful reminder that COVID-19 still has the upper hand in the U.S., even with more than 200 million Americans fully vaccinated.
globalnews.ca
jimihendrix1
Well-Known Member
Could be Denmark as about 74% Vaccination Rate, and South Africa has a 42% Vaccination Rate.
The vaccinations in Denmark are probably causing less severe symptoms. Scientist do say the vaccine cuts down on the rate of severity. This may be further proof.
- Fully vaccinated people with a vaccine breakthrough infection are less likely to develop serious illness than those who are unvaccinated and get COVID-19.
- Even when fully vaccinated people develop symptoms, they tend to be less severe symptoms than in unvaccinated people. This means they are much less likely to be hospitalized or die than people who are not vaccinated.
Last edited:
doublejj
Well-Known Member
Pfizer CEO says fourth Covid vaccine doses may be needed sooner than expected due to omicron
www.cnbc.com
Pfizer CEO says fourth Covid vaccine doses may be needed sooner than expected due to omicron
"When we see real-world data, will determine if the omicron is well covered by the third dose and for how long," Pfizer CEO Albert Bourla told CNBC.
captainmorgan
Well-Known Member
“New CDC data shows that unvaccinated people face a 20-times greater risk of dying from COVID-19 than fully vaccinated people who have also received a booster dose.”
The silver lining of this pandemic is in the end there will be many dead tRUmptards, it seems to be the only cure for them.
The silver lining of this pandemic is in the end there will be many dead tRUmptards, it seems to be the only cure for them.
captainmorgan
Well-Known Member
Hospitals in NYC & around the country are putting a temporary pause on monoclonal antibody treatments because most don't work vs Omicron, except sotrovimab.
captainmorgan
Well-Known Member
A cruise ship is returning to Miami with 48 positive covid cases, the ‘USS: Are You F’N Kidding me!?’ Will be docking soon.
You have to be a special kind of stupid to go on a cruise these days.
You have to be a special kind of stupid to go on a cruise these days.
Roger A. Shrubber
Well-Known Member
i give a shit what they say, i'm not getting a damn shot every month...make the fuckers last at least 6 months or i may join the other teamPfizer CEO says fourth Covid vaccine doses may be needed sooner than expected due to omicron
Pfizer CEO says fourth Covid vaccine doses may be needed sooner than expected due to omicron
"When we see real-world data, will determine if the omicron is well covered by the third dose and for how long," Pfizer CEO Albert Bourla told CNBC.